EMA Refused: Mycograb (recombinant human monoclonal antibody to hsp) — NeuTec Pharma plc

View source ↗

Summary

EMA refused authorization for Mycograb, a recombinant human monoclonal antibody targeting hsp for candidiasis, by NeuTec Pharma plc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis

Drugs mentioned

• Mycograb

Snippet

Status: Refused. Therapeutic area: Candidiasis. MAH: NeuTec Pharma plc. Decision date: 21/03/2007